"eculizumab or ravulizumab: C5 complement inhibitors 19,20,35"
"inebilizumab: CD19 monoclonal antibody 21,35"
Expected headings
"Orbits"
"Brain"
"Spinal cord"
"Acute relapse treatment"
"Long-term immunotherapy"
"Prognosis"
"diencephalic syndrome (e.g. narcolepsy, autonomic dysfunction)"
"associated other autoimmune conditions (e.g. systemic lupus erythematosus (SLE) and Sjögren disease)"
"Additionally, in patients with longstanding disease, often with a history of numerous clinical attacks, rarely a more extensive, confluent, bilateral, symmetric pattern of T2/FLAIR hyperintensities may be seen, which can involve subcortical and deep white matter, external capsules, anterior temporal lobe, and cerebellum 25."
"Acute relapses should be treated promptly, as early intervention significantly improves outcomes. Standard therapy is high-dose intravenous methylprednisolone (1000 mg/day for 3-5 days), followed by an oral corticosteroid taper 35. Plasma exchange should be initiated early, ideally within 2 days of symptom onset, in patients with disabling relapses or inadequate response to corticosteroids; early plasma exchange is associated with full recovery in up to 40% of patients 35. Intravenous immunoglobulin therapy may be considered when plasma exchange is unavailable or contraindicated 35."
"History and etymology"